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Abstract 
Safe delivery of CRISPR/Cas endonucleases remains one of the major barriers to the 
widespread application of in vivo genome editing. We previously reported the utility of 
adeno-associated virus (AAV)-mediated CRISPR/Cas genome editing in the retina; 
however, with this type of viral delivery system, active endonucleases will remain in the 
retina for an extended period, making genotoxicity a significant consideration in clinical 
applications. To address this issue, we have designed a self-destructing "kamikaze" 
CRISPR/Cas system that disrupts the Cas enzyme itself following expression. Four guide 
RNAs (sgRNAs) were initially designed to target Streptococcus pyogenes Cas9 (SpCas9) and 
after in situ validation, the selected sgRNAs were cloned into a dual AAV vector. One 
construct was used to deliver SpCas9 and the other delivered sgRNAs directed against 
SpCas9 and the target locus (yellow fluorescent protein, YFP), in the presence of mCherry. 
Both constructs were packaged into AAV2 vectors and intravitreally administered in 
C57BL/6 and Thyl-YFP transgenic mice. After 8 weeks the expression of SpCas9 and the 
efficacy of YFP gene disruption was quantified. A reduction of SpCas9 mRNA was found in 
retinas treated with AAV2-mediated-YFP/SpCas9 targeting CRISPR/Cas compared to those 
treated with YFP targeting CRISPR/Cas alone. We also show that AAV2-mediated delivery 
of YFP/SpCas9 targeting CRISPR/Cas significantly reduced the number of YFP fluorescent 
cells among mCherry-expressing cells (~85.5% reduction compared to LacZ/SpCas9 
targeting CRISPR/Cas) in the transfected retina of Thyl-YFP transgenic mice. In conclusion, 
our data suggest that a self-destructive "kamikaze" CRISPR/Cas system can be used as a 
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Introduction 
Inherited retinal diseases are disabling disorders of visual function that affect millions of 
people worldwide. With the development of next-generation sequencing and better 
molecular diagnostic techniques, numerous genetic variants across many loci have been 
definitively associated with inherited retinal diseases1' 2 • Despite this increase in our 
understanding of genetic aetiology and potential therapeutic targets, there remains no 
effective treatment for the majority of inherited retinal diseases. Although significant 
progress in gene therapy has been achieved over the last two decades, there are few 
sustained, safe and effective ocular gene therapy for hereditary retinal diseases3-5. 
Advances in genome editing techniques, in particular the recent advances in 
CRISPR/Cas technology6, has renewed excitement in ocular gene-based therapy. The 
CRISPR/Cas system has evolved in archaea and bacteria as a defence against viral intrusion 
and has been adapted to allow efficient editing of mammalian nuclear genomes6• 
CRISPR/Cas-based technology has proven to be a robust means for in vitro correction of 
genetic mutations in mammalian cells and is particularly attractive for treating inherited 
retinal diseases7• A number of in vivo studies in various animal models have yielded 
promising results for pre-emptive therapy for well-characterised monogenic ocular 
diseases. Bakondi et a/.8 and Latella et a/.9 report that successful ablation of the mutated 
rhodopsin gene prevented retinal degeneration in rodent models of severe autosomal 
dominant retinitis pigmentosa following electroporation of the CRISPR/Cas9 system into 
the retina. More recently, Yu et at. 10 demonstrated that CRISPR/Cas9-mediated disruption 
of a neural retina-specific leucine zipper protein (NRL) significantly improved rod survival 
and preserved cone function in a murine model of retinal degeneration. We were able to 
achieve high efficiency genome editing in mouse retina using a dual AAV2-mediated 
CRISPR/Cas9 system11. However, potentially deleterious effects of prolonged over-
expression of CRISPR/Cas endonuclease including elevated off-target cleavage12' 13, and 
cellular immune responses 14 remain important safety hurdles to clinical application. 
To address this, we have designed a self-destructive "kamikaze" CRISPR/Cas system 
that disrupts the CRISPR/Cas gene after active protein expression (Figure 1). To determine 
the efficacy of in vivo genome editing by our "kamikaze" CRISPR/Cas construct, a SpCas9 
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were packaged into a dual AAV2 vector system for intravitreal delivery in Thyl -YFP 
transgenic mice. 
Materials and Methods 
Animals and housing 
All procedures were conducted according to the Association for Research in Vision and 
Ophthalmology Statement for the Use of Animals in Ophthalmic and Vision Research and 
the requirements of National Health and Medical Research Council of Australia (Australian 
Code of Practice for the Care and Use of Animals for Scientific Purposes). Ethics approval 
was obtained from the Animal Ethics Committees of the University of Tasmania (A14827) 
and St. Vincent's Hospital Melbourne (AEC 014/15). Thyl-YFP transgenic mice [B6.Cg-
Tg(Thyl-YFP)16Jrs/J] were obtained from the Jackson Laboratory (mouse stock number: 
003709; Bar Harbor, ME, USA) and bred at the animal facility of the Menzies Institute for 
Medical Research (Hobart, TAS, Australia). C57BL/6 mice were purchased from the Animal 
Resources Centre (Perth, WA, Australia). Mice were housed under standard conditions 
(20°C, 12/12-hour light/dark cycle) with ad libitum access to food and water. 
sgRNA design and vector construction 
Four sgRNAs targeting the SpCas9 sequence were designed using a web-based CRISPR 
design tool (http://crispr.mit.edu). CRISPR/Cas in situ testing was carried out by incubating 
the individual synthetic SpCas9 sgRNA or Lacz sgRNA alone with the recombinant SpCas9 
protein (catalog no. M0386S; New England Biolabs, Ipswich, MA, USA) and the pX551 
plasmid (SpCas9 construct; kindly provided by Feng Zhang, Addgene #60957). Samples 
were run on a 0.8% TAE agarose gel to visualize their cleavage efficiency for SpCas9. Agel 
(catalog no. R0552S; New England Biolabs) digested pX551 plasmid was used as a positive 
control. Four SpCas9 sgRNAs were then cloned into a pX552-CMV-GFP plasmid (modified 
from Addgene #60958, by replacing the hSVNl promoter with a CMV promoter) at the Sapl 
restriction site for in vitro validation . Subsequently, the selected SpCas9 sgRNA (SpCas9 
sgRNA4) was sub-cloned into an AAV package plasmid (pX552-hSYN1-mCherry-YFP 
sgRNA2, sgRNA6 or pX552-LacZ sgRNA) at the Mlul (catalog no. R3198; New England 
Biolabs) restriction site to generate YFP or Lacz targeting kamikaze CRISPR/Cas9 construct. 
For in vitro validation, pX551-CMV-SpCas9 plasmid was modified from pXSSl plasmid by 
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Cell culture and transfection 
Stable YFP expressing HEK293A cells were generated using a lentivirus as previously 
described11• 15 • HEK293A-YFP cells were maintained in Dulbecco's modified Eagle's media 
(DMEM; catalog no. 11965118; Life Technologies Australia, Scoresby, VIC, Australia) 
supplemented with 10% fetal calf serum (Sigma-Aldrich, St. Louis, MO, USA), 2 mM 
glutamine (catalog no. 2503008; Life Technologies Australia), 50 U/mL penicillin-
streptomycin (catalog no. 15070063; Life Technologies Australia) in a humidified 5% CO2 
atmosphere at 37 °C. Transfection was undertaken with FuGENE-HD transfection reagent 
(catalog no. E2311; Promega Australia, Alexandria, NSW, Australia) according to the 
manufacturer's instruction. Briefly, HEK293A-YFP cells were seeded onto a 6-wel l plate 
(2.Sx105 per well) 24 hours before transfection. A mixture of 7.5 µL FuGENE-HD 
transfection reagent with 1500 ng plasmid (750 ng/plasmid was used in dual plasmid 
transfection) in 150 µL Opti-MEM (catalog no. 11058021; Life Technologies Australia) was 
added into each well. For in vitro validation of SpCas9 sgRNA, cells were collected for 
western blot analysis at day 3 after transfection; for in vitro time course analysis, cells 
were harvested at day 1, 2, 3, 5 and 7 days after transfection. 
Western blot analysis 
Cells were collected and lysed in ice-cold Cell Lysis Buffer (Catalog no.89900; Thermo 
Fisher Scientific, Waltham, MA, USA) and sonicated for 10 seconds by an ultrasonic cell 
disruptor (MISONIX Microson XL 2000; Qsonica, Newtown, CT, USA). Total protein was 
quantified by a Bio-Rad protein assay (Catalog no. 5000006; BIO-RAD, Hercules, CA, USA) 
using a microplate reader (Infinite Ml000 Pro; TECAN, Mannedorf, Switzerland). A total of 
10 µg protein samples were separated using NuPAGE™ Novex™ 4-12% Bis-Tris Protein Gels 
(catalog no. NP0321BOX; Life Technologies Australia) and transferred to polyvinylidene 
fluoride membranes (catalog no. 162-0177; BIO-RAD) using the XCell 11™ Blot Module (Life 
Technologies Australia). Membranes were blocked with 5% skim milk in TBS-T (10 mM Tris, 
150 mM NaCl, and 0.05% Tween-20) at room temperature for 1 hour and then incubated 
with mouse monoclonal SpCas9 antibody (1:1000 dilution; MAC133, lot number 2591899; 
Millipore, Billerica, MA, USA) or mouse monoclonal ~-actin antibody (1:2000 dilution; MAB 
1501, lot number 2722855; Millipore) at room temperature for 1 hour. Membranes were 









Page 6 of 41 
6 
secondary antibody (1:5000 dilution; catalog no. A-11045; Life Technologies Australia) at 
room temperature for 1 hour, and developed using the Amersham ECL Prime Western 
Blotting Detection kit (catalog no. RPN2232; GE Healthcare Australia, Parramatta, NSW, 
Australia). The relative levels of SpCas9 protein of each sample was quantified using 
densitometry analysis {lmageJ software-gels analysis) with normalization to ~-actin. 
YFP detection 
YFP expressing HEK293A cells were trypsinized and harvested in PBS. Cells were stained 
with DAPI (5 µg/mL) to exclude the dead cells. The percentage of YFP positive cells was 
then analyzed from live cell population with a Flow Cytometer (BD FACS Canto II; BO 
bioscience, Sparks, MD, USA) and data were analyzed using FACS analysis software 
(FlowJo®; FlowJo LLC, Ashland, OR, USA). 
AAV production 
Recombinant AAV2 viruses were produced in HEK293D cells (kindly provided by Ian 
Alexander, Children's Medical Research Institute, Westmead, NSW, Australia) packaging 
either pX551 plasmid, containing SpCas9, or pX552-mCherry plasmid with the respective 
sgRNAs (SpCas9, YFP or Lacz sgRNA), pseudoserotyped with the AAV2 capsid (pXX2)16, and 
purified using a AAV2pro Purification Kit (catalog no. 6232; Clontech Laboratories, 
Mountain View, CA, USA) as previously described11' 15. Viral titer was determined by real-
time quantitative PCR using a Fast SYBR Green Master Mix (catalog no. 4385612; Life 
Technologies Australia) with the pX551 or pX552 forward and reverse primers 
(Supplementary Table 1). 
Off-target effects assessment 
Off-target mutagenesis for the YFP targeting sgRNAs, YFP sgRNA2 and YFP sgRNA6, as well 
as SpCas9 target ing sgRNA, SpCas9 sgRNA4, were assessed using online prediction tool 
(Cas-OFFinder) in t he Mus musculus genome. Potent ia l off-target effects were further 
investigated using the method described by Chen et a/.17 Briefly, 10 guide RNA sequences 
were designed to contain a single-nucleotide mismatch between the spacer and 
protospacer target at the YFP gene locus targeted by YFP sgRNA6, spanning from 5' to the 
protospacer adjacent motif. These mismatch-containing guide RNAs (sgRNA M2~M20) 
were generated in conventional and kamikaze AAV-CRISPR/Cas9 systems and transfected 
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Zymo Research, Irvine, CA, USA) at day 10 post transfection and T7El assay was performed 
at YFP targeting loci with forward and reverse primers (supplementary table 1) by using an 
EnGen Mutation Detection Kit (catalog no. E3321; New England Biolabs). Mismatch 
cleavages by T7El were analyzed by Image J. For Sanger sequencing, PCR amplicon {885 
bp) from genomic DNA was purified using DNA Clean & Concentrator kit (catalog no. 
D4033; Zymo Research) and were sequenced in-house on the Applied Biosystems 3500 
Genetic Analyzer (Thermo Fisher Scientific) using YFP reverse sequencing primer 
(Supplementary table 1). Sanger files were analyzed for insertions and deletions using the 
inference of CRISPR edits (ICE) tool (https://ice.synthego.com/#/). 
lntravitreal Injection 
For our in vivo time course analysis, a total of 76 C57BL/6 adult mice, aged between 12 and 
14 weeks were randomly separated into two groups, to receive either AAV2-
SpCas9+AAV2-YFP sgRNA2 (n= 39) or AAV2-SpCas9+AAV2-SpCas9 sgRNA/YFP sgRNA2 (n= 
37). For the YFP disruption experiments, a total of 49 Thyl-YFP transgenic mice, aged 
between 16 and 20 weeks, were randomly allocated into three groups; those receiving 
AAV2-SpCas9+AAV2-YFP sgRNA2 (n= 17), AAV2-SpCas9+AAV2-SpCas9 sgRNA/YFP sgRNA2 
(n= 17) or AAV2-SpCas9+AAV2-SpCas9 sgRNA/LacZ sgRNA (n= 15). In addition, another 29 
Thyl-YFP transgenic mice were used to test different YFP sgRNAs. These mice were 
randomly allocated into three groups; those receiving AAV2-SpCas9+AAV2-YFP sgRNA6 (n= 
9), AAV2-SpCas9+AAV2-SpCas9 sgRNA/YFP sgRNA6 (n= 10) or AAV2-SpCas9+AAV2-SpCas9 
sgRNA/LacZ sgRNA {n= 10). 
Mice were anesthetized by intraperitoneal injection of ketamine {60 mg/kg) and 
xylazine (10 mg/kg)11. lntravitreal injection was performed under a surgical microscope. 
After a small puncture was made through the conjunctiva and sclera using a 30-gauge 
needle, a hand-pulled glass micropipette connected to a 10 µL Hamilton syringe (Bio-
Strategy, Broadmeadows, VIC, Australia) was inserted into the vitreous. A total of 1 µL 
dual-viral suspension (AAV2-SpCas9: 2.5x109 vector genomes (vg)/µL with AAV2-YFP 
sgRNA: 2.5x109 vg/µL, AAV2-SpCas9 sgRNA/YFP-sgRNA: 2.5x109 vg/µL or AAV2-SpCas9 
sgRNA/LacZ sgRNA: 2.5x109 vg/µL) was injected into one eye of each mouse using a UMP3-
2 Ultra Micro Pump (World Precision Instruments, Sarasota, FL, USA) at a rate of 200 nl/s. 
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haemorrhaging of the external or internal vessels, retinal detachment was recorded, and 
eyes were excluded from the study. 
Electroretinography (ERG) and Optical Coherence Tomography (OCT) 
At 8 weeks following injection, mice underwent overnight dark-adaptation (~12 hours), 
followed by electroretinography assessment under fully dark-adapted conditions. Details 
for functional assessment have been outlined previously11' 18, with the exception that the 
reference chloride silver electrode was placed around the outside of the eye. ERG analysis 
was as previously described11' 18 and returned the photoreceptor (a-wave), bipolar cell (b-
wave), and ganglion cell dominated (scotopic threshold response, STR) components of the 
waveform. Group data are given as mean (± standard error of the mean [SEM]). 
Following ERG recordings, retinal images were obtained using a spectral domain-
OCT (Bioptigen, Inc., Morrisville, NC, USA). Mice were positioned to capture Optic Nerve 
Head (ONH) centred 1.4 mm-wide horizontal B-scans (consisting of 1000 A-scans). lmageJ 
software (https:/ /imagej.nih.gov/ij/) was used in a masked fashion to quantify total retinal 
thickness (from the inner limiting to Bruch's membrane), retinal nerve fibre layer thickness 
(from the inner limiting membrane to the inner aspect of the inner plexiform layer) and 
outer retinal thickness (from Bruch's membrane to the outer plexiform layer) in each eye. 
Retinal flat-mount, imaging and counting 
Eyes were removed, fixed in ice-cold 4% paraformaldehyde for 1 hour and dissected under 
a dissecting microscope. After removing the cornea, iris and lens, four equally spaced 
radial relaxing incisions, extending two thirds of the way from the retinal periphery to the 
ONH, were made. The sclera and choroid were then removed along with residual vitreous 
and hyaloid vessels, leaving only the retina. The fully dissected retina was stained with 
NucBlue™ Live ReadyProbes™ Reagent (catalog no. R37605; Life Technologies Australia) as 
a nuclear counterstain. Retinal images were captured by a fluorescence microscope (Zeiss 
Axio lmager Microscope; Carl-Zeiss-Strasse, Oberkochen, Germany) equipped with a 
charge-coupled digital camera (Axiocam MRm, Zeiss) and image acquisition software 
(ZEN2, Zeiss) as previously described11. 
The efficiency of YFP disruption was quantified using individual fluorescent images 
captured at x400 magnification. A total of 24 images from three flat-mounted eyes treated 
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SpCas9 sgRNA/YFP sgRNA2 and 36 images from five flat-mounted eyes treated with YFP 
sgRNA2 were quantified manually using lmageJ vl.49 by an experienced grader (FL), 
masked to treatment status. For the second experiment with YFP sgRNA6, 16 images from 
three flat-mounted eyes treated with SpCas9 sgRNA/LacZ sgRNA, 38 images from five flat-
mounted eyes treated with SpCas9 sgRNA/YFP sgRNA6 and 36 images from 6 flat-mounted 
eyes treated with YFP sgRNA6 were quantified. Efficiency for each treatment group was 
determined as the proportion of YFP-negative cells relative to mCherry-expressing cells as 
previously described11. 
Statistical Analysis 
All statistical analyses were performed using Prism 7 software (GraphPad Software, Inc., La 
Jolla, CA, USA). Group data are represented as mean ± SEM unless otherwise noted. Mean 
data were analyzed with unpaired t-tests, one-way or two-way analysis of variance 
(ANOVA) followed by post-hoc analysis {GraphPad Prism 7.0). A value of p < 0.05 was taken 
to be statistically significant. 
Results 
Generation and validation of kamikaze CRISPR/Cas construct in vitro. 
We first validated four sgRNAs (Figure 2A) for SpCas9 targeting using an in situ cleavage 
assay. Robust cleavage of the SpCas9 plasmid (pXSSl) was found when each of the four 
designed SpCas9 sgRNAs were introduced to recombinant SpCas9 protein {Figure 2B). We 
further confirmed the efficacy of SpCas9 gene perturbations by transfection of the SpCas9 
expression construct (pXSS1-CMV-SpCas9) together with SpCas9 targeting CRISPR/Cas 
constructs carrying different SpCas9 sgRNA (pXSS2-SpCas9 sgRNAl-4) into HEK293A cells. 
SpCas9 sgRNA4 had a clear destructive effect on SpCas9 (Figure 2C), reduction of SpCas9 
protein, as well as having a lower off-target score against the human genome as predicted 
by a web-based CRISPR design program (http://crispr.mit.edu). A time course analysis 
showed that SpCas9 protein was progressively reduced in cells following the transfection 
of selected SpCas9 targeting CRISPR/Cas construct (pX552-SpCas9 sgRNA4) compared to 
Lacz sgRNA control (pX552-LacZ sgRNA; p<0.05; Figures 2D and 2E). 
We next re-engineered our kamikaze CRISPR/Cas construct with YFP targeting 
sgRNAs or a Lacz targeting sgRNA {Figure 3A), and the efficacy of YFP gene disruption in 
the YFP-expressing HEK293A cells was assessed. Two days after transfection, we observed 
ti e 
a. 
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a reduction of SpCas9 protein in cells that had received the kamikaze CRISPR/Cas construct 
compared to those cells that had received the conventional CRISPR/Cas construct (Figure 
3B). In terms of efficiency, the percentage of YFP-expressing cells was significantly reduced 
in cells transfected with the YFP targeting kamikaze CRISPR/Cas constructs (SpCas9 
sgRNA/YFP sgRNA2: 10.0±1.0% and SpCas9 sgRNA/YFP sgRNA6: 5.6±0.4% respectively), 
compared to Lacz targeting kamikaze (SpCas9 sgRNA/LacZ sgRNA: 85.9±1.3%) or Lacz 
targeting (Lacz sgRNA: 86.0±1.4%) CRISPR/Cas construct at 10 days after transfection 
(Figures 3C and 3D). Similarly, a lower percentage of YFP expressed cells was also found in 
cells transfected with the YFP targeting CRISPR/Cas construct (VFP sgRNA2: 16.7±2.7% and 
YFP sgRNA6: 7.4±1.4% respectively; Figures 3C and 3D). 
In silica prediction of off-target sites for YFP sgRNA6 and SpCas9 sgRNA4 did not 
produce any significant candidates for testing, as both YFP and SpCas9 sequences were not 
found endogenously in the mouse genome. Next, we created a series of putative off-target 
sites by introducing single-nucleotide mismatch along YFP sgRNA6 sequence and 
compared the editing activity of conventional and kamikaze CRISPR/Cas systems (Figure 
4A). A similar frequency of indels was induced by conventional or kamikaze CRISPR/Cas 
systems for knockout of YFP (Supplementary Figure 1). Almost all guide RNAs with single-
nucleotide mismatches displayed editing activity at day 10 (Figure 4B) with the highest 
editing produced by a mismatch located distal to the PAM (M18) at day 10. A statistically 
reduction of editing activity at M2-M8 and M20 mutant guide RNA positions was observed 
with our kamikaze CRISPR/Cas system compared to the conventional CRISPR/Cas system 
(Figure 4C). 
In vivo delivery of kamikaze CRISPR/ Cas construct in the mouse retina. 
To evaluate whether the reduction of SpCas9 expression by the kamikaze CRISPR/Cas 
construct compromises on-target editing efficiency Thyl-YFP mice received a single 
intravitreal injection of a dual viral suspension of AAV2-SpCas9 along with the YFP 
targeting kamikaze CRISPR/Cas construct (AAV2-SpCas9 sgRNA/YFP sgRNA) or the Lacz 
targeting kamikaze CRISPR/Cas construct (AAV2-SpCas9 sgRNA/LacZ sgRNA) or a single YFP 
targeting CRISPR/Cas construct as a positive control (AAV2-YFP sgRNA2) . The procedures 
for our in vivo study is shown in Figure SA. Eight weeks following treatment, images from 
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positive cells in mice that had received either AAV2-SpCas9 sgRNA/YFP sgRNA or AAV2-YFP 
sgRNA2 compared to AAV2-SpCas9 sgRNA/LacZ sgRNA (Figure SB). Specifically, the 
proportion of retinal YFP/mCherry-expressing cells was reduced to 5.5±1.4% in AAV2-
SpCas9 sgRNA/YFP sgRNA2-treated retina and 7.3±1.3% in AAV2-YFP sgRNA2-treated 
retina, compared with 38.2±1.7% in AAV2-SpCas9 sgRNA/LacZ sgRNA treated eyes. Overall, 
there was a 85.5% (95% Cl: 78.4-92.6) and 80.9% (95% Cl: 74.3-87.5) reduction in YFP 
positive cells in AAV2-SpCas9 sgRNA/YFP sgRNA- and AAV2-YFP sgRNA2-treated retinas, 
respectively, compared to AAV2-SpCas9 sgRNA/LacZ sgRNA-treated eyes (Figure SC). No 
significant difference in the percentage of YFP disruption was found in between AAV2-YFP 
sgRNA2- and AAV2-SpCas9 sgRNA/YFP sgRNA2-treated retinas (P=0.62; Figure SC). This 
was confirmed by using an alternate YFP targeting sgRNA (YFP sgRNAG), where the 
proportion of retinal YFP/mCherry-expressing cells was 17.0±1.3% in AAV2-SpCas9 
sgRNA/YFP sgRNAG-treated retina and 20.6±1.2% in AAV2-YFP sgRNAG-treated retina, 
compared with 40.8±2.0% AAV2-SpCas9 sgRNA/LacZ sgRNA-treated eyes. This represents a 
relative reduction of 49.5% (95% Cl: 43.5-55.5) and 58.3% (95% Cl: 56.4-62.0) in AAV2-
SpCas9 sgRNA/YFP sgRNAG- and AAV2-YFP sgRNAG-treated retinas compared to those that 
had received AAV2-SpCas9 sgRNA/LacZ sgRNA, respectively (Supplementary Figure 2). 
Furthermore, SpCas9 gene perturbations in vivo were confirmed by qPCR. A time 
course analysis showed that SpCas9 mRNA was significantly reduced in the retinas 
following the treatment of AAV2-SpCas9 sgRNA/YFP sgRNA2 compared to AAV2-YFP 
sgRNA2 (p<0.05 at week 8; Supplementary Figure 3). 
Retinal function and structure assessment by electroretinography (ERG) and optical 
coherence tomography (OCT). 
To evaluate the effect of our "kamikaze" CRISPR/Cas construct on retinal function and 
structure, ERG and OCT were performed at 8 weeks after intravitreal injection of viral 
suspensions in Thyl-YFP mouse. Group averaged waveforms elicited using bright and dim 
flashes of light along with the group averaged data from eye injected with YFP targeting 
kamikaze-CRISPR/Cas constructs (AAV2-SpCas9 sgRNA/YFP sgRNA2, Figures GA and 68) and 
YFP targeting CRISPR/Cas constructs (AAV2-YFP sgRNA2, Figures GE and GF) suggest that 
both treatments affected retinal function when compared with the contralateral control 
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construct (AAV2-SpCas9 sgRNA/lacZ sgRNA) treated eyes retained normal retinal function 
(Figure 6C and 6D). OCT analysis suggest that none of the CRISPR/Cas constructs negatively 
impacted retinal structure, as there were no significant differences in retinal nerve fibre 
layer and total ret inal thickness between the vehicle and viral-injected eyes of all three 
groups (Figure 6G-I). 
Discussion 
This study builds on our recent work using AAV2-mediated CRISPR/Cas to edit genes in 
mouse retina11. While CRISPR/Cas9-mediated genome editing has shown promise for 
correcting disease-causing mutations, the potential for genotoxic effects with prolonged 
expression of CRISPR/Cas9 poses a significant barrier to the clinical utility of this 
technology. Several strategies have been employed in an attempt to avoid off-target 
cleavage, including improved guide RNA design19' 20, or modification of Cas9 enzymes21' 22 . 
Such approaches do not avoid accumulation of Cas9, which can increase the overall chance 
of off-target cleavage and immunological response. Our approach was to employ a self-
destructive CRISPR/Cas system that disrupts the CRISPR/Cas enzyme itself after the active 
protein has been expressed. Unlike other approaches, most of which act to control the 
activity of the CRISPR/Cas system via chemical23' 24, and biophysical25' 26 modulation of 
Cas9, our kamikaze CRISPR/Cas system can significantly reduce accumulation of Cas9 
protein in vitro and disrupt AAV-Cas9 construct in vivo, without dramatically compromising 
the efficiency of on-target editing. This approach is similar to that used by Merienne and 
colleagues27 who demonstrated that progressively inactivating the nuclease using a Cas9 
self-inactivating editing system resulted in a lower frequency of off-target cleavage in 
human iPSCs-derived neurons in vitro and in mouse brains via lentiviral-mediated in vivo 
delivery. Chen et al. has also been tested similar self-restrictive CRISPR/Cas system in 
vitro17. While these previous works have shown the feasibility of a self-destructive 
CRISPR/Cas system, our study highlights the effectiveness of an AAV-mediated self-
destructive CRISPR/Cas system for in vivo genome editing in the retina. 
We observed similar efficiencies in YFP gene perturbation between conventional 
and kamikaze CRISPR/Cas system, but also found differences between in vitro and in vivo 
models, especially in SpCas9 sgRNA/YFP sgRNA6 construct {% YFP reduction in vitro: 93.5% 
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58.3%). This difference may be due to a dual AAV2 vector system was employed to deliver 
the kamikaze CRISPR/Cas construct in vivo. We and others have recently demonstrated 
that CRISPR/Cas9 delivered using a dual AAV2 vector can effectively edit the genome in a 
number of organs in adult mice11' 28-30. However, expression of the CRISPR/Cas9 machinery 
requires the receipt of both Cas9 and sgRNA expression cassettes from two separate viral 
vectors, which may significantly reduce editing efficiency. Although a single viral vector 
system employing Cas9 orthologs such as SaCas931 or CjCas932 may provide better in vivo 
editing efficiency, dual-vector systems may still be required for mutation correction as 
they enable delivery of donor templates and appropriate promoter elements. 
An unexpected reduction in retinal function was observed 8 weeks after injection 
of AAV2-SpCas9 sgRNA/YFP sgRNA2 or AAV2-YFP sRNA2. Interestingly, retinal function was 
unaffected in mice treated with AAV2-SpCas9 sgRNA/LacZ sgRNA, therefore, deficits in 
retinal function is not related to the SpCas9 sgRNA construct per se, but may be related to 
either off-target effects of YFP targeting sgRNA or accumulation of non-functional 
fluorescent proteins resulting from CRISPR/Cas9 editing. To further explore this possibility, 
firstly we tested a different YFP sgRNA (sgRNA6 which targets another region of the YFP 
sequence) in vivo. However, a significant decrease in retinal function was still present in 
AAV2-SpCas9 sgRNA/YFP sgRNA6 and AAV2-YFP sgRNA6 treated mice (Supplementary 
Figures 7-9). We then searched the mouse genome for potential off-target sites for two 
YFP sgRNAs and SpCas9 sgRNA by in silico prediction (Cas-OFFinder) and performed whole 
exome sequencing on the treated mouse retinae. No significant candidate genes for the 
off-target sites were found by in silico prediction or by whole exome sequencing 
(Supplementary Results). Therefore, it may be more likely that the reduction of retinal 
function arises from accumulation of mutated fluorescent proteins. Although fluorescence 
proteins such as GFP and YFP have been widely used in neuroscience research33, 
accumulation of non-functional proteins resulting from on-target deletions (indel) may 
lead a deleterious effect on retinal protein homeostasis34. Moreover, a recent study also 
indicated that large on-target deletions could lead to potential genotoxicity29• Whether 
such mechanisms account for the functional deficits observed in our study requires further 
investigation. Although no retinal toxicity was observed by over-expression of Cas9 
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conducted over a relatively short period of time (8 weeks). As such the long-term safety 
profile and whether the potentially deleterious effects caused by prolonged over-
expression of truncated gene products in the retina, as potentially caused by our self-
destructive CRISPR/Cas system, requires further investigation. 
In summary, we describe and characterise a self-destructive "kamikaze" 
CRISPR/Cas system for in vivo genome editing in the retina. This self-destructive kamikaze 
CRISPR/Cas system can effectively reduce the expression of SpCas9 in the mouse retina, 
without substantially sacrificing on-target editing efficiency. Therefore, our AAV2-
mediated self-destructive CRISPR/Cas may be a useful tool for genome editing in the 
retina, especially when combined with high fidelity forms of CRISPR/Cas. 
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Figure 1. Schematics of Kamikaze CRISPR/Cas system. A dual AAV vector system was 
used. One viral vector was used to deliver SpCas9 and the other delivered sgRNAs against 
SpCas9 and the target locus (YFP), in the presence of mCherry. 
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Figure 2. Design and validation of SpCas9 sgRNA. (A) Schematic diagram of SpCas9 sgRNA 
design. Blue: selected SpCas9 sgRNA targeted sites. Green: PAM sequences. (B) In situ 
validation of SpCas9 sgRNAs. (C) In vitro validation of SpCas9 sgRNAs. Representative 
western blot of SpCas9 protein expression in cells 2 days after co-transfected with SpCas9 
and the individual SpCas9 sgRNA plasmids. (D) Representative western blot of the time 
course of SpCas9 expression. Cells were harvested on day 1, 2, 3, 5 and 7 after transfection 
with SpCas9 and selected SpCas9 sgRNA {#4) plasmids. (E) Relative fold change of SpCas9 
protein expression normalized to 13-actin. Mean ± SEM for 3 independent replicates. 
Statistical analysis between control and sgRNA-transfected group was performed using 
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Figure 3. In vitro validation of kamikaze CRISPR/Cas construct. (A) Schematic of plasmid 
constructs for in vitro validation. (B) Representative Western blots of SpCas9 protein 
expression in cells co-transfected with SpCas9 and kamikaze (SpCas9 sgRNA/YFP sgRNA 
and SpCas9 sgRNA/LacZ sgRNA) or non-kamikaze (YFP sgRNA and Lacz sgRNA) constructs. 
(C) Representative images of YFP expression in cells co-transfected with kamikaze (SpCas9 
sgRNA/YFP sgRNA and SpCas9 sgRNA/LacZ sgRNA) or non-kamikaze (YFP sgRNA and Lacz 
sgRNA) constructs. scale bar: 100 µm. (D) Percentage YFP disruption was assessed by FACS 
at 10 days after transfection. Mean ± SEM for 3 independent replicates. Statistical analysis 
between control and sgRNA-transfected group was performed using one-way ANOVA 
followed by Tukey's multiple comparisons test (**p < 0.001). 
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Figure 4. Kamikaze CRISPR/Cas reduced potential off-target in vitro. (A) Sequences of 
mismatch containing YFP-targeting guide RNAs. (B) T7El assay showing CRISPR/Cas9 
editing activity of these single-nucleotide mismatches at day 10 after transfection. PCR 
products containing amplicons derived from mutant YFP or from wild-type YFP only are 
indicated by the arrows and asterisks, respectively. (C) Analysis of indels by ICE tool, 
indicating the difference in mismatch related CRISPR editing between kamikaze YFP 
targeting CRISPR/Cas system and conventional YFP targeting CRISRP/Cas system. 
Mean± SEM for 3 independent replicates. Statistical analysis between kamikaze YFP 
targeting CRISPR/Cas system and conventional YFP targeting CRISRP/Cas system was 
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Figure 5. Kamikaze CRISPR/Cas-mediated genome editing of retinal cells in vivo. (A) High 
magnification of retinal flat-mount images, showing differences in YFP expression 
following AAV2-mediated delivery of SpCas9 sgRNA/YFP sgRNA (n= 5), YFP sgRNA2 (n= 5) 
or SpCas9 sgRNA/LacZ sgRNA (n= 3). Scale bar: 20 µm. (B) Percentage YFP disruption was 
assessed by manual cell counting. Mean± SEM for 3-5 independent replicates. Statistical 
analysis between groups was performed using one-way ANOVA followed by Tukey's 
multiple comparisons t est (**p < 0.001). 
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Figure 6. Effect of AAV2-mediated CRISPR/Cas administration on retinal function. 
Averaged ERG waveforms at selected intensities for control (black traces) and SpCas9 
sgRNA/YFP sgRNA2 (n= 4, red traces; A), SpCas9 sgRNA/LacZ sgRNA (n = 4, blue traces; C) 
and YFP sgRNA2 (n= 5, green traces; E) injected eyes. Group average (± SEM) 
photoreceptoral (a-wave), bipolar cell (b-wave), amacrine cell (oscillatory potentials, OPs) 
and ganglion cell (scotopic threshold response, STR) amplitude relative to contralateral 
control eyes (%) for each group (B, D and F). Effect of SpCas9 sgRNA/YFP sgRNA2, SpCas9 
sgRNA/LacZ sgRNA and YFP sgRNA2 on retinal structure measured with OCT (G). Group 
average (± SEM) retinal nerve fibre layer thickness (H) for SpCas9 sgRNA/YFP sgRNA2 
treated (filled red, n= 4) and their contralateral controls (unfilled red, n= 4), SpCas9 
sgRNA/LacZ sgRNA treated (filled blue, n= 4) and their contralateral controls (unfilled blue, 
n= 4) and YFP sgRNA2 treated (filled green, n= 5) and their contralateral controls (unfilled 
green, n=5). Total retinal thickness (I). Statistical analysis between injected and control 
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Supplementary Table 1. Sequence of primers for sgRNA cloning, vector construction, 
sequencing and qPCR analysis. 
Supplementary Figure 1. Spectrum and frequency of indels for knockout of YFP . 
Supplementary Figure 2. Quantification of YFP disruption in the retina. 
Supplementary Figure 3. Time course of SpCas9 mRNA expression in the mouse retina . 
Supplementary Figure 4. SpCas9 sgRNA/YFP sgRNA2 decreased retinal function. 
Supplementary Figure 5. YFP sgRNA2 alone affects inner retinal function. 
Supplementary Figure 6. SpCas9 sgRNA/LacZ sgRNA does not affect retinal function . 
Supplementary Figure 7. SpCas9 sgRNA/YFP sgRNA6 decreased retinal function. 
Supplementary Figure 8. YFP sgRNA6 alone affects inner retinal function. 
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Supplementary methods: 
• Quantitative PCR to detect SpCas9 expression in the retina. 
• Genomic DNA extraction from mouse retinas and whole exome sequencing. 
Supplementary Result: Whole exome sequencing showed no off-target effect of AAV2-
SpCas9 sgRNA/YFP sgRNA6. 
Supplementary Information: Uncropped agarose gel and western blot images. 
Supplementary methods: 
Quantitative PCR to detect SpCas9 expression in the retina 
Total RNA from mouse retinas were extracted and purified using commercial kits (RNeasy 
Mini Kit; catalog no. 74104; Qiagen, Chadstone, VIC, Australia) in accordance with the 
manufacturer's instructions. RNA was subsequently reverse-transcribed into 
complementary DNA (cDNA) using a high-capacity RT kit (catalog no. 4374996; Life 
Technologies Australia) and quantitative PCR was performed using a Fast SYBR Green 
Master Mix (catalog no. 4385612; Life Technologies Australia) with the SpCas9 forward 
and reverse primers as well as mCherry forward and reverse primers (Supplementary Table 
1). The relative expression levels of SpCas9 was calculated using the 1111Ct method with 
normalization to mCherry. 
Genomic DNA extraction from mouse retinas and whole exome sequencing 
Genomic DNA from two retinas treated with SpCas9 sgRNA/YFP sgRNA6 and two 
· contra lateral retinas were extracted using commercial Genomic DNA Purification Kits 
(QIAGEN, Puregene Core Kit A, Lot no. 8570335; RNase A Solution, Catalog no. 158922; 
Puregene Proteinase K, Catalog no. 158918) and dissolved in TE buffer. Whole exome 
sequencing and standard bioinformatics analyses were performed by Beijing Genomics 
Institute (BGI). Briefly, whole exome enrichment was carried out using the SureSelectxr 
Mouse All Exon Kit (Agilent) and sequencing was performed on NovaSeq 6000 with 150bp 
paired-end reads. Raw reads were filtered and the resulting high-quality, clean data were 
aligned to the mouse reference genome (mmlO) using Burrows-Wheeler Aligner (BWA) 
v0.7.15 (https://www.ncbi.nlm.nih.gov/pubmed/20080505). 
The variants were filtered using the following criteria: (1) SNVs were excluded to 
focus only on indels; (2) indel variants shared between treated retinas and contralateral 
untreated retinas were excluded; (3) known indels were excluded by comparing to dbSNP 
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build 138; (4) homozygous indels were excluded. As for indel analysis, homology between 
sgRNA sequence and sequences around the indel site in the mouse reference genome 
were evaluated. Nucleotide sequences around the indel site were obtained using 
Mutalyzer {https://mutalyzer.nl/) 
(https://onlinelibrary.wiley.com/doi/abs/10.1002/humu.20654). Alignment between the 
20bp sgRNA sequence (both YFP sgRNA6 and SpCas9 sgRNA4 and in both sense and 
antisense orientation) (excluding the PAM) and the sequences provided by Mutalyzer were 
carried out using MAFFT (https://mafft.cbrc.jp/alignment/server/) 
(https ://academic.oup.com/bib/advance-article/doi/10.1093/bib/bbx108/4106928). Off-
target effects were considered when MAFFT showed ungapped alignment between these 
sequences, with fewer than five nucleotide mismatches and presence of correct PAM site 
in the reference sequence. 
Supplementary Result: 
Whole exome sequencing showed no off-target effect of AAV2-SpCas9 sgRNA/YFP 
sgRNA6 
Whole exome sequencing produced consistent coverage across all four samples {153.33-
155.68X). A total of 303 indel variants were detected in all four samples and 120 indels 
were shared between treated retinas and contralateral untreated retinas and were 
therefore removed. About 79 indels were unique in treated retinas and of these were 
removed due a match in dbSNP and/or were homozygous. When searching for putative 
off-target sequences around the remaining indels in the reference genome, we did not find 
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Supplementary Table 1. Sequence of primers for sgRNA cloning, vector construction, 
sequencing and qPCR analysis. 
Primer name Sequence Purpose 
SpCas9 gRNAl FWD ACCGCAAGAAGTACAGCATCGGCC sgRNA cloning 
SpCas9 gRNAl REV AACGGCCGATGCTGTACTTCTTGC sgRNA cloning 
SpCas9 gRNA2 FWD ACCGTACAGCATCGGCCTGGACAT sgRNA cloning 
SpCas9 gRNA2 REV AACATGTCCAGGCCGATGCTGTAC sgRNA cloning 
SpCas9 gRNA3 FWD ACCGCCGATGCTGTACTTCTTGT sgRNA cloning 
SpCas9 gRNA3 REV AACACAAGAAGTACAGCATCGGC sgRNA cloning 
SpCas9 gRNA4 FWD ACCGCAGAGTTGGTGCCGATGTCC sgRNA cloning 
SpCas9 gRNA4 REV AACGGACATCGGCACCAACTCTGC sgRNA cloning 
U6p-Mlul FWD AGCACGCGTGAGGGCCTAmCCCATGAT Vector construct 
SpCas9 sgRNA GCTACGCGTAAAAAAAGCACCGACTCGGT Vector construct 
scaffold-Miu! REV 
YFP sgRNA2 FWD CACCGCGAGGAGCTGTTCACCGGGG sgRNA cloning 
YFP sgRNA2 REV AAACCCCGGTGAACAGCTCCTCGC sgRNA cloning 


















EYFP SURVEYOR REV 
EYFP Seq-REV 
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CGCAAATGGGCGGTAGGCGTG T7E1 PCR 
CTGGTAGCTCAGGTAGTGGTTG T7E1 PCR 
GAAGTCGTGCTGCTTCATGTGG Sequencing 
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Supplementary Figure 1. Spectrum and frequency of indels induced by conventional (YFP 
sgRNA; n=3) or kamikaze CRISPR/Cas systems (Cas9 sgRNA/YFP-sgRNA; n=3) for knockout 
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Supplementary Figure 2. Quantification of YFP disruption in the retina. The percentage of 
YFP disruption following AAV2-mediated delivery of SpCas9 sgRNA/YFP sgRNA6, YFP 
sgRNA6 or SpCas9 sgRNA/LacZ sgRNA was assessed by manual cell counting. 
Representative data are shown for 3-5 retinas and expressed as the Mean± SEM. 
Statistical analysis between groups was performed using one-way ANOVA followed by 
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Supplementary Figure 3 
























Supplementary Figure 3. Time course of SpCas9 mRNA expression in the mouse retina. 
SpCas9 mRNA were isolated from the mouse retina administrated with AAV2-SpCas9 
sgRNA/YFP sgRNA2 or AAV2-YFP sgRNA2 at 1, 2, 3, 4, 5, 6 and 8 weeks after intravitreal 
injection. Relative fold change of SpCas9 expression was normalized by week 1 from each 
treatment group. Representative data are shown for 5-6 retinas per group/time point and 
expressed as Mean ± SEM. Statistical analysis between groups was performed using Two-
way ANOVA followed by Sidak's multiple comparisons test. a, YFP sgRNA2: 1 vs 8 weeks, 
p=0.002. b, SpCas9/YFP sgRNA: 1 vs 8 weeks, p=0.7043. c, YFP sgRNA2 vs SpCas9/YFP 
sgRNA, p=0.0142. 
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Supplementary Figure 4. SpCas9 sgRNA/YFP sgRNA2 decreased 
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retinal 
function. {A) Averaged ERG waveforms at selected intensities for control (n=4, black) and 
treated eyes (n=4, red). (B) Groups average photoreceptoral (a-wave) saturated amplitude 
for contralateral control {unfilled) and treated eyes {filled). {C) Photoreceptoral sensitivity 
to light. (D) Intensity response characteristics across the entire range of 
intensities. (E) Bipolar cell amplitude. (F) Bipolar cell sensitivity to light. {G) Inner retinal 
amacrine cell mediated response (oscillatory potentials). Data are expressed as the 
Mean± SEM. Statistical analysis between groups was performed using two-tailed Student's 
t-test. Asterisks denotes significance *P<0.05, **P<0.01, ***P<0.001. 
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Supplementary Figure 5 YFP sgRNA2 alone affects inner retinal function. (A) Averaged ERG 
waveforms at selected intensities for control (n=S, black) and treated eyes (n=S, 
green). (B) Groups average (±SEM) photoreceptoral (a-wave) saturated amplitude for 
contralateral control (unfilled) and treated eyes (filled). (C) Photoreceptoral sensitivity to 
light. (D) Intensity response characteristics across the entire range of intensities. (E) Bipolar 
cell amplitude. (F) Bipolar cell sensitivity to light. (G) Inner retinal amacrine cell 
mediated response (oscillatory potentials). Data are expressed as the Mean± SEM. 
Statistical analysis between groups was performed using two-tailed Student's t-test. 
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Supplementary Figure 6 
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Supplementary Figure 6. SpCas9 sgRNA/LacZ sgRNA does not affect retinal 
function. (A) Averaged ERG waveforms at selected intensities for control (n=3, black) and 
treated eyes (n=3, blue). (B) Groups average (±SEM) photoreceptoral (a-wave) saturated 
amplitude for contra lateral control (unfilled) and treated eyes 
(filled). (C) Photoreceptoral sensitivity to light. (D) Intensity response characteristics across 
the entire range of intensities. (E) Bipolar cell amplitude. (F) Bipolar cell sensitivity to light. 
(G) Inner retinal amacrine cell mediated response (oscillatory potentials). Data are 
expressed as the Mean± SEM. Statistical analysis between groups was performed using 
two-tailed Student's t-test. 
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Supplementary Figure 7. SpCas9 sgRNA/YFP sgRNA6 decreased retinal function . (A) 
Averaged ERG waveforms at selected intensities for control (n=lO, black) and treated eyes 
(n=l0, red). (B) Groups average (±SEM) photoreceptoral (a-wave) saturated amplitude for 
contralateral control (unfilled) and treated eyes (filled). (C) Photoreceptoral sensitivity to 
light. (D) Intensity response characteristics across the entire range of intensities. (E) Bipolar 
cell amplitude. (F) Bipolar cell sensitivity to light. (G) Inner retinal amacrine cell mediated 
response (oscillatory potentials). Data are expressed as the Mean± SEM. Statistical 
analysis between groups was performed using two-tailed Student's t-test. Asterisks 
denotes significance *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. 
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Supplementary Figure 8. YFP sgRNA6 alone affects inner retinal function. (A) Averaged 
ERG waveforms at selected intensities for control (n=8, black) and treated eyes (n=8, 
green). (B) Groups average photoreceptoral (a-wave) saturated amplitude for contra lateral 
control (unfilled) and treated eyes (filled). (C) Photoreceptoral sensitivity to light. (D) 
Intensity response characteristics across the entire range of intensities. (E) Bipolar cell 
amplitude. (F) Bipolar cell sensitivity to light. (G) Inner retinal amacrine cell mediated 
response (oscillatory potentials). Data are expressed as the Mean± SEM. Statistical 
analysis between groups was performed using two-tailed Student's t-test. Asterisks 
denotes significance. *P<0.05, **P<0.01. 
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Supplementary Figure 9. SpCas9 sgRNA/LacZ sgRNA does not affect retinal function. (A) 
Averaged ERG waveforms at selected intensities for control (n=8, black) and treated eyes 
(n=8, blue). (B) Groups average photoreceptoral (a-wave) saturated amplitude for 
contralateral control (unfilled) and treated eyes (filled). (C) Photoreceptoral sensitivity to 
light. (D) Intensity response characteristics across the entire range of intensities. (E) Bipolar 
cell amplitude. (F) Bipolar cell sensitivity to light. (G) Inner retinal amacrine cell mediated 
response (oscillatory potentials). Data are expressed as the Mean± SEM. Statistical 
analysis between groups was performed using two-tailed Student's t-test. 
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